The Latest Breaking News from GSK

The CDC has clarified and narrowed its recommendations for which older adults should get an RSV vaccine.

Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed

Allergies happen when your immune system overreacts to a normally harmless substance like dust or pollen. Hay fever, hives and anaphylaxis are all types of allergic reactions.

Price of asthma inhalers has more than doubled amid scarcity and added costs after GSK exited Nigerian market in 2023.

There's been some reports of Guillain-Barré syndrome in older adults who got the vaccines. But health officials still recommend that this population get the shots, in consultation with their doctors.

Amid macroeconomic challenges like high inflation, recession threats, and global uncertainties, value stocks such as GSK (GSK), Expedia Group (EXPE), and Albertsons (ACI) offer promising opportunities for savvy bargain hunters. Read on.

BP and Shell shares today hindered FTSE 100 progress after oil prices fell to their lowest level since February.

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…